
Von Willebrand’s Disease – Pipeline Insight, 2024
Description
Von Willebrand’s Disease – Pipeline Insight, 2024
DelveInsight’s, “Von Willebrand’s Disease – Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Von Willebrand’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Von Willebrand’s Disease: Overview
People with von Willebrand disease (VWD) have a problem with a protein called von Willebrand factor (VWF). When a blood vessel is injured and bleeding occurs, VWF helps cells in the blood (called platelets) to form a clot to stop the bleeding. People with VWD have reduced levels of VWF, or their VWF does not work normally, so it takes longer for blood to clot and for bleeding to stop. VWD is the most common bleeding disorder and is generally less severe than other bleeding disorders. It is estimated that up to 1% of the world’s population suffers from VWD but, because many people have mild symptoms, only a small number of them know they have VWD. For most people with VWD, the disorder causes little or no disruption to their lives except when they bleed heavily (e.g. during surgery or dental procedures, because of a serious injury, during childbirth, or due to heavy periods). However, with all forms of VWD, there can be bleeding problems.
""Von Willebrand’s Disease - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Von Willebrand’s Disease pipeline landscape is provided which includes the disease overview and Von Willebrand’s Disease treatment guidelines. The assessment part of the report embraces, in depth Von Willebrand’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Von Willebrand’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Von Willebrand’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Von Willebrand’s Disease.
This segment of the Von Willebrand’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Von Willebrand’s Disease Emerging Drugs
- BT200: Band Therapeutics
Further product details are provided in the report……..
Von Willebrand’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Von Willebrand’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Von Willebrand’s Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Von Willebrand’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Von Willebrand’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Von Willebrand’s Disease drugs.
Von Willebrand’s Disease Report Insights
- Von Willebrand’s Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Von Willebrand’s Disease drugs?
- How many Von Willebrand’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Von Willebrand’s Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Von Willebrand’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Von Willebrand’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Band Therapeutics
- TagCyx Biotechnologies
- China Biologic Products
- Thrombotargets Corporation
- Sanofi
- BT200
- TAGX 0004
- Human von Willebrand Factor
- TT 173
- BIVV001
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Von Willebrand’s Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Von Willebrand’s Disease – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- BT200: Band Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery stage Products
- Comparative Analysis
- TAGX 0004: TagCyx Biotechnologies
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Von Willebrand’s Disease Key Companies
- Von Willebrand’s Disease Key Products
- Von Willebrand’s Disease- Unmet Needs
- Von Willebrand’s Disease- Market Drivers and Barriers
- Von Willebrand’s Disease- Future Perspectives and Conclusion
- Von Willebrand’s Disease Analyst Views
- Von Willebrand’s Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.